Ninur (Nitrofurantoin)

Nitrofurantoin, the active ingredient in Ninur, is a nitrofuran antibiotic presented as an oral tablet for systemic use. It is indicated for the treatment of uncomplicated urinary tract infections caused by susceptible bacteria, primarily in adult patients.

GNH USA supplies Ninur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products and reliable logistics for global healthcare providers. The product complies with European Union pharmacopeial standards and is manufactured under GMP conditions. It is distributed through GNH USA's established network to meet the needs of diverse markets.

Nitrofurantoin is used primarily for infections of the urinary tract caused by susceptible bacteria.

- Uncomplicated urinary tract infection: eradicates the causative bacteria and resolves dysuria, frequency and urgency. - Acute cystitis: provides rapid symptom relief and bacterial clearance in adult women. - Recurrent urinary tract infection prophylaxis: reduces the frequency of new infections when administered over a prolonged period.

Adverse reactions may occur with nitrofurantoin therapy and vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Loss of appetite: reduced desire to eat. - Headache: transient cranial discomfort. - Diarrhea: loose stools, usually self‑limiting. - Metallic taste: transient alteration of taste perception. - Mild skin rash: localized erythema or itching.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or fibrosis, potentially life‑threatening. - Hepatic injury: jaundice, elevated liver enzymes. - Severe allergic reactions: anaphylaxis, angioedema. - Hemolytic anemia: especially in patients with G6PD deficiency. - Peripheral neuropathy: numbness or tingling in extremities. - Agranulocytosis: marked reduction in white blood cells.

Before initiating nitrofurantoin, clinicians should consider several safety aspects. - Renal function assessment: avoid use in patients with creatinine clearance <60 mL/min. - Pregnancy and lactation: use only if benefits outweigh potential risks. - G6PD deficiency: contraindicated due to risk of hemolysis. - Long‑term therapy: monitor for pulmonary or hepatic toxicity. - Concomitant nephrotoxic drugs: exercise caution to prevent renal impairment. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nitrofurantoin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce nitrofurantoin absorption. - Probenecid: increases nitrofurantoin plasma concentrations, raising toxicity risk. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Methenamine: concurrent use can diminish antimicrobial activity.

Moderate Interactions (Monitor Closely): - NSAIDs: combined renal stress may impair kidney function. - Diuretics: altered urinary concentration can affect drug excretion. - Fluoroquinolones: concurrent use may increase risk of tendon disorders.